Guidelines for the Use of Antiepileptic Drugs in the Periconception Period: Interpretations and Research Progress

doi:10.19803/j.1672-8629.20240436

Abstract

Abstract: Objective To investigate the impact of antiepileptic drugs on mothers and fetuses during the periconceptional period in order to provide a reference for obstetricians and pharmacists. Methods Research progress in the correlations between various antiepileptic drugs and major congenital malformations, adverse perinatal outcomes, and neurodevelopment, as well as the effects of folic acid supplementation during the periconceptional period on maternal and fetal health was summarized and recommendations were offered. Results Antiepileptic drugs were correlated with congenital malformations, adverse perinatal outcomes and neurodevelopment. During the periconceptional period, epileptic seizures needed to be brought under effective control via medications while the potential impact of these drugs on the fetus had to be assessed. Conclusion The rational use of antiepileptic drugs combined with folic acid supplementation is crucial to the health of mothers with epilepsy and fetuses.

Key words: Epilepsy, Antiseizure Medication, People with Epilepsy of Childbearing Potential, Folic Acid, Teratogenesis, Perinatal Outcomes, Guideline Interpretation

CLC Number:

R984

WANG Ran, FENG Xin. Guidelines for the Use of Antiepileptic Drugs in the Periconception Period: Interpretations and Research Progress[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 357-360.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240436

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I3/357

References

[1] Epilepsy Special Committee, Neurology Branch, Chinese Medical Doctor Association. Association Antiepileptic Therapy in Pregnant Women: a Chinese Expert Consensus[J].Journal of Chinese Physician(中国医师杂志),2015, 17(7): 969-971.
[2] Chinese Society of Electroencephalography and Epilepsy. Chinese guidelines for the Management of Women with Epilepsy during Periconceptional Period[J].Chinese Journal of Neurology, 2021, 54(6): 539-544.
[3] CHANG RSK, LUIKHK, IP W, et al.Update to the Hong Kong Epilepsy Guideline: Evidence-Based Recommendations for Clinical Management of Women with Epilepsy throughout the Reproductive Cycle[J].Hong Kong Medical Journal, 2020, 26(5): 421-431.
[4] KINNEY MO, MORROW J. Epilepsy in Pregnancy[J].British Medical Journal, 2016, 7(2),353: i2880.
[5] HARDEN C, PENNELL P, KOPPEL B, et al.Practice Parameter Update: Management Issues for Women with Epilepsy-Focus on Pregnancy(an Evidence-Based Review): Teratogenesis and Perinatal Outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society[J].Neurology, 2009, 73(2): 133-141.
[6] PACK AM, OSKOUI M, ROBERSON SW, et al.Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After in Utero Exposure to Antiseizure Medication: Practice Guideline from the AAN, AES, and SMFM[J].Neurology, 2024, 102(11): e209279.
[7] CHRISTENSEN J, VESTERGAARD C, BECH BH.Maternal Death in Women with Epilepsy: Smaller Scope Studies[J].Neurology, 2018, 91(18): e1716-e1720.
[8] MACDONALD SC, BATEMAN BT, MCELRATH TF, et al.Mortality and Morbidity During Delivery Hospitalization among Pregnant Women with Epilepsy in the United States[J].JAMA neurology, 2015, 72(9): 981-988.
[9] National Perinatal Epidemiology Unit-Conducting Robust Research. Saving Lives, Improving Mothers' Care-Lessons Learned to Inform Maternity Care from the UK and Ireland confidential Enquiries into Maternal Deaths and Morbidity2013-15[EB/OL].[2024-12-19].https://www.npeu.ox.ac.uk/mbrrace-uk/presentations/saving-lives-improving-mothers-care#saving-lives-improving-mothers-care-lessons-learned-to-inform-maternity-care-from-the-uk-and-ireland-confidential-enquiries-into-maternal-deaths-and-morbidity-2013%E2%80%9315.
[10] KAELIN ANDREA A, XIA J, SERVANTE JA, et al. Routine Ultrasound for Fetal Assessment before 24 Weeks' Gestation[J].Cochrane Database of Systematic Reviews2021, 8(8): CD014698.
[11] ELGIN TG, BERGER JN, KALUARACHCHI DC, et al.Outcomes of Infants with Birthweights less than 501 g Compared to Infants Weighing 501-750 g at a Center Utilizing First Intention High Frequency Jet Ventilation[J].Front Pediatr, 2024, 12: 1392079.
[12] LEDET III LF, PLAISANCE CJ, DANIEL CP, et al.Spina Bifida Prevention: a Narrative Review of Folic Acid Supplements for Childbearing Age Women[J].Cureus, 2024, 16(1): e53008.
[13] ORNOYA, ECHEFU B, BECKER M.Valproic Acid in Pregnancy Revisited: Neurobehavioral, Biochemical and Molecular Changes Affecting the Embryo and Fetus in Humans and in Animals: a Narrative Review[J].International Journal of Molecular Sciences, 2023, 25(1): 390.
[14] HEBERT J, CONANT SN, HOLMES LB, et al.The North American Antiepileptic Drug Pregnancy Registry: a Canadian Subgroup Analysis[J].Canadian Journal of Neurological Sciences , 2023, 50(2): 214-220.
[15] TOMSON T, BATTINO D, BONIZZONI E, et al.Comparative Risk of Major Congenital Malformations with Eight Different Antiepileptic Drugs: a Prospective Cohort Study of the EURAP Registry[J].Lancet Neurol, 2018, 17(6): 530-538.
[16] HERNANDEZ-DIAZ S, SMITH CR, SHEN A, et al.Comparative Safety of Antiepileptic Drugs during Pregnancy[J].Neurology, 2012
78(21): 1692-1699.
[17] COHEN JM, ALVESTAD S, SUAREZ EA, et al.Comparative Risk of Major Congenital Malformations with Antiseizure Medication Combinations vs Valproate Monotherapy in Pregnancy[J].Neurology, 2024, 102(2): e207996.